Table 2 Immunomodulatory effect of nilotinib versus placebo treatment on synovial histopathology
From: A proof-of-concept study with the tyrosine kinase inhibitor nilotinib in spondyloarthritis
Marker | Nilotinib | Placebo | ||
|---|---|---|---|---|
Week 0 | Week 12 | Week 0 | Week 12 | |
CD68 lining | 1.7 (1.7–3.0) | 0.3 (0.0–2.0) | 2.8 (1.2–3.0) | 2.3 (1.7–3.0) |
CD68 sublining | 2.0 (1.3–2.3) | 0.0 (0.0–1.3) | 2.0 (1.0–3.0) | 1.7 (1.3–2.0) |
CD163 lining | 2.7 (2.0–2.7) | 0.7 (0.0–2.0) | 2.8 (0.7–3.0) | 2.7 (2.7–2.7) |
CD163 sublining | 2.3 (2.3–2.7) | 1.3 (0.3–2.0) | 2.3 (1.4–3.0) | 2.3 (2.3–2.3) |
c-Kit | 1.0 (0.3–2.3) | 0.0 (0.0–0.7) | 0.0 (0.0–0.8) | 1.3 (0.3–2.3) |